Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    KalVista Pharmaceuticals ...

    NASDAQ: KALV · Real-Time Price · USD
    13.03
    0.08 (0.62%)
    At close: Aug 15, 2025, 2:34 PM
    0.62%
    Bid 13.02
    Market Cap 650.9M
    Revenue (ttm) n/a
    Net Income (ttm) -183.44M
    EPS (ttm) -3.69
    PE Ratio (ttm) -3.53
    Forward PE -3.69
    Analyst Buy
    Ask 13.04
    Volume 412,959
    Avg. Volume (20D) 1,202,650
    Open 13.00
    Previous Close 12.95
    Day's Range 12.80 - 13.25
    52-Week Range 7.30 - 16.32
    Beta 0.04

    About KALV

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol KALV
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for KALV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    KalVista Pharmaceuticals Inc. is scheduled to release its earnings on Sep 4, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +25.71%
    KalVista Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
    2 months ago
    +9.49%
    KalVista Pharmaceuticals shares are trading higher after the company announced new data and findings for sebetralstat.
    news image

    4 days ago · businesswire.com

    KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

    CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines ...

    news image

    1 week ago · businesswire.com

    KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted six newl...

    news image

    3 weeks ago · businesswire.com

    KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

    CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Med...

    news image

    1 month ago · businesswire.com

    KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

    CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United ...

    news image

    1 month ago · zacks.com

    KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?

    KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.

    news image

    1 month ago · businesswire.com

    KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

    CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended Apr...

    news image

    1 month ago · seekingalpha.com

    KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning

    FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience an...

    news image

    1 month ago · reuters.com

    US FDA approves KalVista Pharma's swelling disorder drug

    KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.

    news image

    1 month ago · businesswire.com

    KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

    CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralst...

    news image

    1 month ago · businesswire.com

    KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

    CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pend...

    Add to Watchlist